Treating fibroblasts with HDAC inhibitors results in significant paracrine stimulation of tumor growth, which suggests that high-dose HDAC inhibitors would likely impact the stromal compartment adversely in a therapeutic setting. This evidence concerns the gene HDAC9 and neoplasm.